Lancet:延迟氨甲环酸抗纤溶药物治疗显著降低急性重症出血患者生存率

2017-11-08 zhangfan MedSci原创

研究发现,急性严重出血是严重威胁患者生命的症状,片刻的延误都会导致氨甲环酸治疗效果显著降低

抗纤溶药物可减少创伤出血和产后出血导致的死亡。近日研究人员考察了延迟抗纤溶治疗对创伤出血和产后出血患者生存率的影响。

本研究为荟萃分析研究,研究人员统计了1946-2017年间的相关资料,急性严重出血患者人数超过1000例的抗纤溶药物随机试验有资格纳入本次研究。研究的主要终点是出血死亡

2项氨甲环酸用于急性出血(创伤和产后出血)的临床研究纳入本次荟萃分析,总计40138名患者,共发生了3558例患者死亡事件,其中40%的患者死于失血。大部分(884 /1408 [63%])出血患者在症状发生后12小时死亡,产后出血死亡率在胎儿娩出后2-3小时达到峰值。研究发现,氨甲环酸可显著降低总的出血死亡率(OR 1.20, 95% CI 1.08-1.33; p=0.001),其效果不受出血位置的影响。延迟治疗导致治疗收益降低。即刻治疗可提高70%的生存率(OR 1.72, 95% CI 1.42-2.10)。出血症状发生3小时内,治疗每延迟15分钟,患者的生存率下降10%,3小时后治疗无临床意义。氨甲环酸不会增加血栓风险且不受出血位置的影响,延迟治疗不会影响氨甲环酸对血栓事件的效果。

研究发现,急性严重出血是严重威胁患者生命的症状,片刻的延误都会导致氨甲环酸治疗效果显著降低。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829313, encodeId=4d74182931384, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Feb 24 06:07:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932599, encodeId=1609193259998, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Oct 14 07:07:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256608, encodeId=0037125660824, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 10 04:07:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260077, encodeId=9fcb2600e732, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXprUCFDMuY1SXH96r8MdtExF6fhSNLulicdUBcsodicYROXqf5icqDWFAOicfEqYtDcjL6HvrQrvmO1/0, createdBy=db841700299, createdName=克勤, createdTime=Thu Nov 09 21:15:55 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259713, encodeId=208a259e137c, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Nov 08 13:31:43 CST 2017, time=2017-11-08, status=1, ipAttribution=)]
    2018-02-24 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1829313, encodeId=4d74182931384, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Feb 24 06:07:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932599, encodeId=1609193259998, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Oct 14 07:07:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256608, encodeId=0037125660824, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 10 04:07:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260077, encodeId=9fcb2600e732, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXprUCFDMuY1SXH96r8MdtExF6fhSNLulicdUBcsodicYROXqf5icqDWFAOicfEqYtDcjL6HvrQrvmO1/0, createdBy=db841700299, createdName=克勤, createdTime=Thu Nov 09 21:15:55 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259713, encodeId=208a259e137c, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Nov 08 13:31:43 CST 2017, time=2017-11-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1829313, encodeId=4d74182931384, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Feb 24 06:07:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932599, encodeId=1609193259998, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Oct 14 07:07:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256608, encodeId=0037125660824, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 10 04:07:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260077, encodeId=9fcb2600e732, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXprUCFDMuY1SXH96r8MdtExF6fhSNLulicdUBcsodicYROXqf5icqDWFAOicfEqYtDcjL6HvrQrvmO1/0, createdBy=db841700299, createdName=克勤, createdTime=Thu Nov 09 21:15:55 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259713, encodeId=208a259e137c, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Nov 08 13:31:43 CST 2017, time=2017-11-08, status=1, ipAttribution=)]
    2017-11-10 guoyibin
  4. [GetPortalCommentsPageByObjectIdResponse(id=1829313, encodeId=4d74182931384, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Feb 24 06:07:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932599, encodeId=1609193259998, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Oct 14 07:07:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256608, encodeId=0037125660824, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 10 04:07:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260077, encodeId=9fcb2600e732, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXprUCFDMuY1SXH96r8MdtExF6fhSNLulicdUBcsodicYROXqf5icqDWFAOicfEqYtDcjL6HvrQrvmO1/0, createdBy=db841700299, createdName=克勤, createdTime=Thu Nov 09 21:15:55 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259713, encodeId=208a259e137c, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Nov 08 13:31:43 CST 2017, time=2017-11-08, status=1, ipAttribution=)]
    2017-11-09 克勤

    非常好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1829313, encodeId=4d74182931384, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Feb 24 06:07:00 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932599, encodeId=1609193259998, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Oct 14 07:07:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256608, encodeId=0037125660824, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 10 04:07:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260077, encodeId=9fcb2600e732, content=非常好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzXprUCFDMuY1SXH96r8MdtExF6fhSNLulicdUBcsodicYROXqf5icqDWFAOicfEqYtDcjL6HvrQrvmO1/0, createdBy=db841700299, createdName=克勤, createdTime=Thu Nov 09 21:15:55 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=259713, encodeId=208a259e137c, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Nov 08 13:31:43 CST 2017, time=2017-11-08, status=1, ipAttribution=)]
    2017-11-08 flysky120

    学习一下知识了

    0

相关资讯

Lancet:氨甲环酸为产后出血最佳治疗药物

氨甲环酸可显着减少产后出血导致的妇女死亡,当产后出血发生时,应第一时间给予氨甲环酸

J Am Acad Dermatol:口服氨甲环酸治疗黄褐斑

目的:黄褐斑是亚洲人常见的一种色素性疾病,其治疗具有挑战性。口服氨甲环酸(TA)已经成为难治性黄褐斑一个潜在的治疗。但目前缺乏其安全性和有效性的大规模研究。我们试图评估口服TA对亚洲人口黄褐斑的治疗效果和不良影响。方法:对2010年1月-2014年6月在皮肤中心就诊接受口服TA的患者进行了回顾性分析。结果:研究共纳入了561例患者,其中91.4%为女性。治疗时间中位数为4个月。大多数患者(503

NEJM:氨甲环酸治疗接受心脏手术患者,益处和风险并存

氨甲环酸降低了接受心脏手术患者的出血风险,但目前尚不清楚这是否会改善患者的预后。此外,人们还担忧氨甲环酸可能会有促血栓形成和致痫作用。在该项2×2析因设计的试验中,研究人员随机分配预计接受冠状动脉手术并且有围手术期并发症风险的患者接受阿司匹林或安慰剂,氨甲环酸或安慰剂。研究人员还报告了氨甲环酸比较的结果。主要结果是手术后30天内的死亡和血栓性并发症(非致死性心肌梗死,卒中,肺栓塞,肾衰竭或肠梗塞)

J Arthroplasty:全髋关节置换术,局部 VS.静脉注射氨甲环酸

已知氨甲环酸可减少全髋关节置换术围手术期失血。采用随机对照试验研究设计,共纳入了139名患者,分别接受2 g氨甲环酸局部应用或静脉注射。标准化术前和术后的方案。结果,与局部应用组患者相比 (160.3 [g] ± 63.8, 188.4 [g] ± 68.5; P = .014),静脉注射组患者血液和血红蛋白的损失量较低(1195.0 ± 485.9 mL, 1442.7 ± 562.7 mL;

Br J Clin Pharmacol:哪些因素决定外用氨甲环酸治疗全膝关节置换术后出血的疗效?

2017年7月,发表在《Br J Clin Pharmacol》的一项由中国科学家进行的研究考察了外用氨甲环酸治疗全膝关节置换术后出血的量化疗效。

JBJS:关节内应用氨甲环酸可减少全膝术后失血

接受全膝关节置换(TKA)的患者中大约有1/3在术后需要输血1-3个单位,氨甲环酸是一种人工合成的抗纤维蛋白溶解的药物,可以经静脉有效的控制TKA术后失血。而局部使用氨甲环酸更加便于临床管理,可以使其在出血部位形成最大的药物浓度,减少甚至消除药物全身吸收所带来的风险。 为了研究局部(关节内)应用氨甲环酸对单侧TKA输血和失血带来的影响,来自英国James Cook大学